Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cyclo Therapeutics, Inc. Market Cap
From what 3 stock analysts predict, the share price for Cyclo Therapeutics, Inc. (CYTH) might increase by 48.44% in the next year. This is based on a 12-month average estimation for CYTH. Price targets go from $0.95 to $0.95. The majority of stock analysts believe CYTH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assignedCYTH 1 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Cyclo Therapeutics, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CYTH. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CYTH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason McCarthy Maxim Group | Hold | Downgrade | Aug 27, 2024 | |
| Lucas Ward Ascendiant Capital | Buy | $0.95 | Maintains | Aug 26, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Neutral | $0.95 | Downgrade | Aug 23, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $3 | Reiterates | Aug 16, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $3 | Reiterates | May 31, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $3 | Initiates | May 1, 2024 |
| Lucas Ward Ascendiant Capital | Buy | $2.6 | Initiates | Apr 22, 2024 |
| Jason McCarthy Maxim Group | Buy | $4 | Upgrade | Sep 27, 2023 |
| Jason McCarthy Maxim Group | Hold | Downgrade | Mar 21, 2023 | |
Maxim Group | Buy | $12 | Initiates | Dec 17, 2020 |
When did it IPO
1995
Staff Count
8
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. N. Scott Fine
Market Cap
$21.0M
In 2023, CYTH generated $1.1M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CYTH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ResearchAndMarkets.com has released the "Niemann-Pick disease - Pipeline Insight, 2024" report, detailing insights on 10+ companies and 12+ pipeline drugs for the disease.
Why It Matters - The report's insights on Niemann-Pick disease pipeline drugs signal potential investment opportunities in biotech firms focused on rare diseases, influencing stock performance and market sentiment.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Cyclo Therapeutics reported its Q3 2024 financial results, highlighting significant advancements in clinical and corporate areas, positioning the company for future growth.
Why It Matters - Cyclo Therapeutics' advancements in clinical and corporate sectors indicate potential growth, impacting stock performance and investor sentiment in the biotech sector.
Thu, 14 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cyclo Therapeutics, Inc. (CYTH) reported a quarterly loss of $0.26 per share, worse than the expected loss of $0.17, and improved from a loss of $0.29 per share a year earlier.
Why It Matters - Cyclo Therapeutics reported a larger-than-expected loss, indicating potential financial difficulties and impacting investor confidence and stock performance.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Cyclo Therapeutics (Nasdaq: CYTH) reported positive preliminary data from its Phase 3 study of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1 (NPC1).
Why It Matters - Positive preliminary data from Cyclo Therapeutics' Phase 3 study could indicate potential approval for Trappsol® Cyclo™, impacting future revenue and stock performance significantly.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Kahn Swick & Foti, LLC is investigating the proposed merger between Cyclo Therapeutics, Inc. (CYTH) and Rafael Holdings, Inc. (RFL) for potential fairness to shareholders.
Why It Matters - The investigation into Cyclo Therapeutics' merger with Rafael Holdings could impact share prices, reflecting concerns over fairness and the adequacy of the merger process for shareholders.
Thu, 22 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Monteverde & Associates is investigating Cyclo Therapeutics' proposed merger with Rafael Holdings, where Cyclo stock will convert to Rafael shares.
Why It Matters - The investigation into Cyclo Therapeutics' merger with Rafael Holdings could impact shareholder value, as legal actions may influence stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
